Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07770646 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Pragmatic Trial of Interleukin-17 Inhibition Versus Janus Kinase Inhibition After Tumor Necrosis Factor-alpha Inhibitor Failure in Axial Spondyloarthritis

StatusNot Yet Recruiting
PhasePhase 4
Started2026-09-14
View on ClinicalTrials.gov ↗

Amendment history

2026-09-03
Study Status, Arms and Interventions, Outcome Measures v1
Secondary endpointsdetails revised at 4 of 36 entries
2026-08-12
Original filing
The purpose of this study is to determine the feasibility of conducting a pragmatic trial of IL-17i versus JAKi in adults with axial spondyloarthritis (axSpA) who have failed at least one tumor necrosis factor-alpha inhibitor (TNFi), to estimate the effectiveness of IL-17i versus JAKi at 16 weeks and to determine additional effectiveness measures, safety, and treatment persistence of IL-17i versus JAKi
Trial Details
NCT Number NCT07770646
Lead Sponsor The University of Texas Health Science Center, Houston
Conditions Axial Spondyloarthritis (AxSpA)
Enrollment 40 participants
Start Date 2026-09-14
Primary Completion 2028-09-15 (estimated)
Study Completion 2029-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-09-09